NEUROCRINE BIOSCIENCES INC (NBIX)
US64125C1099 - Common Stock
Taking everything into account, NBIX scores 8 out of 10 in our fundamental rating. NBIX was compared to 569 industry peers in the Biotechnology industry. NBIX has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. NBIX is evaluated to be cheap and growing strongly. This does not happen too often! With these ratings, NBIX could be worth investigating further for value and growth and quality investing!.
1. Profitability
1.1 Basic Checks
In the past year NBIX was profitable.
NBIX had a positive operating cash flow in the past year.
Each year in the past 5 years NBIX has been profitable.
In the past 5 years NBIX always reported a positive cash flow from operatings.
1.2 Ratios
With an excellent Return On Assets value of 10.92%, NBIX belongs to the best of the industry, outperforming 96.83% of the companies in the same industry.
Looking at the Return On Equity, with a value of 14.19%, NBIX belongs to the top of the industry, outperforming 96.65% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 13.96%, NBIX belongs to the top of the industry, outperforming 97.00% of the companies in the same industry.
NBIX had an Average Return On Invested Capital over the past 3 years of 9.89%. This is significantly below the industry average of 15.31%.
The 3 year average ROIC (9.89%) for NBIX is below the current ROIC(13.96%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 10.92% | ||
| ROE | 14.19% | ||
| ROIC | 13.96% |
ROA(3y)6.18%
ROA(5y)8.97%
ROE(3y)8.92%
ROE(5y)13.75%
ROIC(3y)9.89%
ROIC(5y)11.96%
1.3 Margins
With an excellent Profit Margin value of 17.21%, NBIX belongs to the best of the industry, outperforming 96.83% of the companies in the same industry.
In the last couple of years the Profit Margin of NBIX has grown nicely.
Looking at the Operating Margin, with a value of 26.23%, NBIX belongs to the top of the industry, outperforming 97.18% of the companies in the same industry.
NBIX's Operating Margin has improved in the last couple of years.
NBIX's Gross Margin of 98.52% is amongst the best of the industry. NBIX outperforms 97.71% of its industry peers.
In the last couple of years the Gross Margin of NBIX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 26.23% | ||
| PM (TTM) | 17.21% | ||
| GM | 98.52% |
OM growth 3Y-12.58%
OM growth 5Y20.67%
PM growth 3Y-30.22%
PM growth 5Y23.12%
GM growth 3Y-0.38%
GM growth 5Y-0.21%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so NBIX is still creating some value.
NBIX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, NBIX has more shares outstanding
NBIX has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 11.06 indicates that NBIX is not in any danger for bankruptcy at the moment.
NBIX has a Altman-Z score of 11.06. This is amongst the best in the industry. NBIX outperforms 86.42% of its industry peers.
There is no outstanding debt for NBIX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 11.06 |
ROIC/WACC1.35
WACC10.37%
2.3 Liquidity
A Current Ratio of 4.37 indicates that NBIX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 4.37, NBIX is in line with its industry, outperforming 49.21% of the companies in the same industry.
NBIX has a Quick Ratio of 4.26. This indicates that NBIX is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 4.26, NBIX perfoms like the industry average, outperforming 50.26% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.37 | ||
| Quick Ratio | 4.26 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 100.54% over the past year.
NBIX shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 70.09% yearly.
Looking at the last year, NBIX shows a very strong growth in Revenue. The Revenue has grown by 25.72%.
NBIX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 33.13% yearly.
EPS 1Y (TTM)100.54%
EPS 3Y23.01%
EPS 5Y70.09%
EPS Q2Q%51.22%
Revenue 1Y (TTM)25.72%
Revenue growth 3Y21.74%
Revenue growth 5Y33.13%
Sales Q2Q%24.72%
3.2 Future
Based on estimates for the next years, NBIX will show a very strong growth in Earnings Per Share. The EPS will grow by 44.72% on average per year.
Based on estimates for the next years, NBIX will show a quite strong growth in Revenue. The Revenue will grow by 15.24% on average per year.
EPS Next Y69.3%
EPS Next 2Y61.04%
EPS Next 3Y54.33%
EPS Next 5Y44.72%
Revenue Next Year24.34%
Revenue Next 2Y20.46%
Revenue Next 3Y19.25%
Revenue Next 5Y15.24%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 33.69, which means the current valuation is very expensive for NBIX.
Based on the Price/Earnings ratio, NBIX is valued cheaper than 95.06% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 29.20, NBIX is valued at the same level.
With a Price/Forward Earnings ratio of 20.02, NBIX is valued on the expensive side.
Based on the Price/Forward Earnings ratio, NBIX is valued cheaper than 94.89% of the companies in the same industry.
NBIX's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 24.00.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 33.69 | ||
| Fwd PE | 20.02 |
4.2 Price Multiples
96.12% of the companies in the same industry are more expensive than NBIX, based on the Enterprise Value to EBITDA ratio.
NBIX's Price/Free Cash Flow ratio is rather cheap when compared to the industry. NBIX is cheaper than 95.59% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 28.91 | ||
| EV/EBITDA | 17.29 |
4.3 Compensation for Growth
NBIX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
NBIX has an outstanding profitability rating, which may justify a higher PE ratio.
NBIX's earnings are expected to grow with 54.33% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.49
PEG (5Y)0.48
EPS Next 2Y61.04%
EPS Next 3Y54.33%
5. Dividend
5.1 Amount
No dividends for NBIX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NEUROCRINE BIOSCIENCES INC
NASDAQ:NBIX (11/22/2024, 8:00:00 PM)
After market: 125.65 0 (0%)125.65
+0.65 (+0.52%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap12.72B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 33.69 | ||
| Fwd PE | 20.02 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)0.49
PEG (5Y)0.48
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 10.92% | ||
| ROE | 14.19% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 26.23% | ||
| PM (TTM) | 17.21% | ||
| GM | 98.52% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.37 | ||
| Quick Ratio | 4.26 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)100.54%
EPS 3Y23.01%
EPS 5Y
EPS Q2Q%
EPS Next Y69.3%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)25.72%
Revenue growth 3Y21.74%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y